Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2026-06-15
Summary
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Conditions
- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Neoplasms
- Colorectal Tumors
- Neoplasms, Colorectal
Interventions
- DRUG
-
JDQ443
KRAS G12C inhibitor, oral
- DRUG
-
MEK inhibitor, oral
- DRUG
-
CDK4/6 inhibitor, oral
- BIOLOGICAL
-
EGFR inhibitor, intravenous
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-24
- Primary Completion
- 2026-09-30
- Completion
- 2026-09-30
- FDA Drug
- Yes
Countries
- United States
- Belgium
- France
- Germany
- Italy
- Singapore
- South Korea
- Spain
Study Locations
More Related Trials
-
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
NCT03574649 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
NCT05815186 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ladarixin With Sotorasib in Advanced NSCLC
NCT05815173 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
NCT05118854 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT02974725 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
NCT04622228 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
NCT00254384 ·Status: COMPLETED ·Phase: PHASE1
-
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
NCT07249879 ·Status: RECRUITING ·Phase: PHASE1
-
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828112 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410 ·Status: RECRUITING ·Phase: PHASE3
-
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
NCT00633568 ·Status: TERMINATED ·Phase: PHASE3
-
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
NCT05400577 ·Status: WITHDRAWN ·Phase: PHASE2
-
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
NCT05045404 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
NCT06731413 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113 ·Status: TERMINATED ·Phase: PHASE1
-
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT01102231 ·Status: COMPLETED ·Phase: PHASE2
-
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04921358 ·Status: TERMINATED ·Phase: PHASE3
-
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
NCT00985855 ·Status: COMPLETED ·Phase: PHASE2